chemotherapy-induced nausea and vomiting
Conditions
Interventions
Palonosetron plus dexamethasone:Palonosetron plus dexamethasone
ondansetron plus dexamethasone:Palonosetron plus dexamethasone
Sponsors
Childrens Hospital of Chongqing Medical University
Eligibility
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: New diagnosis of children with malignant solid tumors, older than 5 years of age, no chemotherapy contraindicated based on blood routine, liver and kidney function and electrocardiogram examination; no history of other related antiemetics, expected survival time more than 3 months, chemotherapy regimens containing highly emetogenic (cisplatin more than 100 mg/m2), informed consent was obtained.
Exclusion criteria
Exclusion criteria: Radiotherapy was received during trial; patients with digestive tract obstruction;patients with severe heart disease, kidney disease, metabolic disorders;patients with epilepsy or using psychotropic drugs and narcotics; antiemetics was used within 24 hours or CINV was observed prior to chemotherapy; patients with brain metastases; vomiting caused by intracranial pressure; patients allergic to 5 - HT3 receptor antagonist; have contraindications to chemotherapy; patients were participating in or have participated in another clinical trial within 2 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence of nausea;incidence of vomiting;Safety evaluatio; | — |
Contacts
Public ContactChao Yang
Outcome results
None listed